Morana Globeways Holdings L... Net Worth

The estimated Net Worth of Morana Globeways Holdings L... is at least $1.88 Milione dollars as of 12 January 2021. Morana L owns over 200,000 units of Cullinan Oncology stock worth over $1,883,621 and over the last 4 years Morana sold CGEM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Morana L CGEM stock SEC Form 4 insiders trading

Morana has made over 1 trades of the Cullinan Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently Morana bought 200,000 units of CGEM stock worth $4,200,000 on 12 January 2021.

The largest trade Morana's ever made was buying 200,000 units of Cullinan Oncology stock on 12 January 2021 worth over $4,200,000. On average, Morana trades about 200,000 units every 0 days since 2021. As of 12 January 2021 Morana still owns at least 104,762 units of Cullinan Oncology stock.

You can see the complete history of Morana L stock trades at the bottom of the page.

Insiders trading at Cullinan Oncology

Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke e Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.

What does Cullinan Oncology do?

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Complete history of Morana L stock trades at Cullinan Oncology

Cullinan Oncology executives and stock owners

Cullinan Oncology executives and other stock owners filed with the SEC include:

• Dr. Patrick A. Baeuerle Ph.D.,
  Co-Founder & Acting Chief Scientific Officer of Biologics
• Owen P. Hughes Jr.,
  Strategic Advisor
• Dr. Jeffrey Jones M.B.A., M.D., M.P.H.,
  Chief Medical Officer
• Steve Andre,
  Chief HR Officer
• Rose Weldon,
  VP of Communications
• Kerry Whalen,
  Sr. Director of Preclinical & Early Devel.
• Dr. Jennifer Michaelson Ph.D.,
  Chief Devel. Officer of Biologics
• Leigh Zawel Ph.D.,
  Chief Scientific Officer of Small Molecules
• Corinne Savill Ph.D.,
  Acting Chief Bus. Officer
• Raymond T. Keane,
  Chief Legal Officer & Sec.
• Nate Nguyen,
  Director of Accounting & Controller
• Jeffrey Trigilio,
  CFO & Treasurer
• Nadim Ahmed,
  Pres, CEO & Director
• Vision Scs Jovan Embiricos ...,
  
• Anthony Rosenberg,
  
• Morana Jovan Embiricos,
  10% owner
• Jacquelyn L Sumer,
  Chief Legal Officer
• Nadim Ahmed,
  President and CEO
• Raymond T Keane,
  Chief Legal Officer
• Jon Marc Wigginton,
  Chief Medical Officer
• Owen Hughes,
  President and CEO
• Leigh Zawel,
  See Remarks
• Morana Globeways Holdings L...,
  
• Ansbert Gadicke,
  Director
• Oncology Impact Fund L.P.On...,
  
• Oncology Impact Fund L.P.On...,
  
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Michaelson,
  Chief Scientific Officer
• David P. Ryan,
  
• Patrick Baeuerle,
  Chief Scientific Officer
• Bioscience I 2017 Ltd Jovan...,
  
• Stephen W Webster,
  
• Thomas Ebeling,
  
• Anne Marie Martin,
  
• Jeffrey Trigilio,
  Chief Financial Officer
• Jeffrey Alan Jones,
  Chief Medical Officer
• Corrine Savill,
  Chief Business Officer
• Mary Kay Fenton,
  Chief Financial Officer
• David D. Meek,
  
• Mary Thistle,